Insights Client login
Insights Client login

Medtech companies: optimize your IP strategy in Europe

Print Friendly, PDF & EmailTélécharger
Published by Frédérique Durieux Anne-Laure Deleuze, Ph.D Masahiro Tahara and Julien Guesnier
Published on 31 Jul 2024
Linkedin Twitter

Published by

Frédérique Durieux

Senior Partner
Head of the Grenoble Office

Anne-Laure Deleuze, Ph.D

Partner

Masahiro Tahara

Japanese Patent Attorney
European Patent Attorney

Julien Guesnier

French Patent Attorney
European Patent Attorney

Published by

Frédérique Durieux

Senior Partner
Head of the Grenoble Office durieux@Regimbeau.eu

Anne-Laure Deleuze, Ph.D

Partner deleuze@Regimbeau.eu

Masahiro Tahara

Japanese Patent Attorney
European Patent Attorney tahara@Regimbeau.eu

Julien Guesnier

French Patent Attorney
European Patent Attorney guesnier@regimbeau.eu
Take an appointment

Related insights

More insights
Publications - 01 Jul 2025

G1/24: The description of a patent must be referred when interpreting the claims… and so what?

By Yves de Saint-Pern
#Patents #Brevets
Publications - 03 Jun 2025

Patentability of dosage regimen claims

By Gaëlle Jan, Ph.D
#Patents #Pharmaceuticals
Publications - 28 Apr 2025

On the patentability of mushrooms according to the UPC

By Aurélia Vavasseur, Ph.D
#Patents #UPC #Brevets #JUB #Patentability #Biotechnology #Biotechnology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.